NMC Guidelines For Competency-Based Training Programme For DM Medical Genetics
Factor VII Deficiency: Its Causes, Symptoms, Treatments, And More - WebMD
Factor VII deficiency is a rare genetic disorder. It occurs when your body can't produce enough clotting factor VII, which helps in healing wounds. It can be hereditary or be caused by an underlying medical condition. Factor VII deficiency can result in excessive bleeding due to a wound or surgery.
Here is all you need to know about factor VII deficiency, along with its causes, symptoms, and treatments.
Your body produces 20 different clotting or coagulation factors. These are proteins that are produced by your body to heal wounds with blood clots.
Factor VII, also called proconvertin, is one such clotting factor produced by the liver. It requires vitamin K for its production. Along with other clotting factors and blood cells, it promotes blood clotting at the site of an injury. It forms normal blood clots and closes the wound to prevent blood loss.
When your body can't produce enough factor VII or when it doesn't work properly, you can get factor VII deficiency. During this condition, your body can't form blood clots, which can result in a wound bleeding too much.
Factor VII deficiency was first studied by Dr. Alexander, which is why it is also known as Alexander's disease. It is also known as proconvertin deficiency or prothrombin conversion accelerator deficiency. It is a rare genetic disorder, which means you can inherit this condition at birth. It can also be caused by other underlying health issues.
Factor VII deficiency is a very rare condition and is known to affect only one in 300,000 to 500,000 individuals. There are two types of this condition depending on the causes:
Inherited factor VII deficiency. Factor VII production depends on the FVII gene in your body. If both your parents have a mutation in the FVII gene, you can inherit two copies of the defective gene. This is called autosomal recessive inheritance, which can result in congenital or inherited factor VII deficiency.
This type of factor VII deficiency is present from birth. But the symptoms may start showing at any age. Severe deficiency can cause symptoms in infants.
Acquired or non-inherited factor VII deficiency. This type of factor VII deficiency is not inherited but is acquired after birth. It can be due to underlying health conditions that prevent factor VII from functioning properly. It can also be caused by medicines that prevent blood clotting.
Acquired factor VII deficiency is more common than the inherited form. The following underlying issues can cause acquired factor VII deficiency:
The symptoms of factor VII deficiency can vary depending on the severity of the disease. These are its common symptoms:
Factor VII deficiency can be diagnosed by checking for a family history of bleeding disorders. It can be diagnosed while testing for underlying diseases. Your doctor will also check you for symptoms like excessive bleeding and delayed blood clotting.
The following tests can be done to check for factor VII deficiency:
1. Clotting tests. Tests like prothrombin time and activated partial thromboplastin time can find out how long it takes for your blood to clot. If you have normal activated partial thromboplastin time and longer prothrombin time, you may have factor VII deficiency.
2. Factor assays. A test known as factor VII assay can help measure the amount of factor VII in your blood. If you have low levels of factor VII, then you may be diagnosed with its deficiency.
3. Prenatal diagnosis. If you have a family history of bleeding disorders, umbilical cord blood can be tested when you are pregnant. Sometimes, genetic analysis is also done to confirm the condition.
Factor VII deficiency can be treated using these clotting agents, which promote blood clotting and prevent bleeding:
Recombinant factor VIIa. This is a replacement therapy to help increase the levels of factor VII in your body. Lab-made or recombinant factor VIIa is injected continuously into your body to replenish its levels in your blood. Novoseven is the preferred recombinant factor VIIa drug that helps treat factor VII deficiency, especially the inherited type.
Prothrombin complex concentrates. Prothrombin is clotting factor II, which helps promote blood clotting. It is injected into your blood with other clotting factors in the form of prothrombin complex concentrates to control bleeding. But, the levels of clotting factors in these concentrates may vary.
Fresh frozen plasma and cryoprecipitate. These contain a mixture of continuously frozen and thawed plasma with clotting factors such as factor VIII and fibrinogen. They can be injected into your bloodstream to promote blood clotting and stop bleeding. This treatment is more economical, but it is less effective and may cause more blood clotting.
Antifibrinolytic agents. Antifibrinolytics like aminocaproic acid are agents that promote blood clotting. They are used to treat bleeding disorders like hemophilia. They are also used to improve the symptoms and prevent bleeding when you have factor VII deficiency.
The treatment of underlying diseases causing factor VII deficiency is important. Conditions such as liver disease and vitamin K deficiency must be treated appropriately to resolve factor VII deficiency.
If you are taking medicines like antibiotics or blood thinners, your doctor may stop those and prescribe you alternative medicines.
Factor V Deficiency: Causes, Symptoms, And Diagnosis - Healthline
What is factor V deficiency?
Factor V deficiency is also known as Owren's disease or parahemophilia. It's a rare bleeding disorder that results in poor clotting after an injury or surgery. Factor V deficiency shouldn't be confused with factor V Leiden mutation, a much more common condition that causes excessive blood clotting.
Factor V, or proaccelerin, is a protein made in your liver that helps convert prothrombin into thrombin. This is an important step in the blood clotting process. If you don't have enough factor V or if it doesn't work properly, your blood may not clot effectively enough to stop you from bleeding. There are different levels of severity of factor V deficiency based on how little or how much factor V is available to the body.
Factor V deficiency may also occur at the same time as factor VIII deficiency, producing more severe bleeding problems. The combination of factor V and factor VIII deficiencies is considered to be a separate disorder.
Factor V deficiency may be inherited or acquired after birth.
Hereditary factor V deficiency is rare. It's caused by a recessive gene, which means that you have to inherit the gene from both of your parents in order to show symptoms. This form occurs in about 1 in 1 million people.
Acquired factor V deficiency may be caused by certain medications, underlying medical conditions, or an autoimmune reaction.
Conditions that might affect factor V include:
Phenotypic Consequences Of Genetic Variation At Hemizygous Alleles ...
Sotos JF, Dodge PR, Muirhead D, Crawford JD, Talbot NB . Cerebral gigantism in childhood. A syndrome of excessively rapid growth with acromegalic features and a nonprogressive neurologic disorder. N Engl J Med 1964; 271: 109–116.
Cole TRP, Hughes HE . Sotos syndrome: a study of the diagnostic criteria and natural history. J Med Genet 1994; 31: 20–32.
Kurotaki N, Imaizumi K, Harada N, Masuno M, Kondoh T, Nagai T et al. Haploinsufficiency of NSD1 causes Sotos syndrome. Nat Genet 2002; 30: 365–366.
Douglas J, Hanks S, Temple IK, Davies S, Murray A, Upadhyaya M et al. NSD1 mutations are the major cause of Sotos syndrome and occur in some cases of Weaver syndrome but are rare in other overgrowth phenotypes. Am J Hum Genet 2003; 72: 132–143.
Rio M, Clech L, Amiel J, Faivre L, Lyonnet S, Le Merrer M et al. Spectrum of NSD1 mutations in Sotos and Weaver syndromes. J Med Genet 2003; 40: 436–440.
Kurotaki N, Harada N, Shimokawa O, Miyake N, Kawame H, Uetake K et al. Fifty microdeletions among 112 cases of Sotos syndrome: Low copy repeats possibly mediate the common deletion. Hum Mutat 2003; 22: 378–387.
Türkmen S, Gillessen-Kaesbach G, Meinecke P, Albrecht B, Neumann LM, Hesse V et al. Mutations in NSD1 are responsible for Sotos syndrome, but are not a frequent finding in other overgrowth phenotypes. Eur J Hum Genet 2003; 11: 858–865.
Kamimura J, Endo Y, Kurotaki N, Kinoshita A, Miyake N, Shimokawa O et al. Identification of eight novel NSD1 mutations in Sotos syndrome. J Med Genet 2003; 40: e126.
Visser R, Shimokawa O, Harada N, Kinoshita A, Ohta T, Niikawa N et al. Identification of a 3.0-kb major recombination hotspot in patients with Sotos Syndrome who carry a common 1.9-Mb microdeletion. Am J Hum Genet 2005; 76: 52–67.
Kurotaki N, Stankiewicz P, Wakui K, Niikawa N, Lupski JR . Sotos syndrome common deletion is mediated by directly oriented subunits within inverted Sos-REP low-copy repeats. Hum Mol Genet 2005; 14: 535–542.
Lupski JR . Genomic disorders: structural features of the genome can lead to DNA rearrangements and human disease traits. Trends Genet 1998; 14: 417–422.
Schmickel RD . Contiguous gene syndromes: a component of recognizable syndromes. J Pediatr 1986; 109: 231–241.
Shaffer LG, Ledbetter DH, Lupski JR . Molecular Cytogenetics of Contiguous Gene Syndrome: Mechanisms and Consequences of Gene Dosage Imbalance. The Metabolic and Molecular Basis of Inherited Disease. 8th edition. V. I. New York: The McGraw-Hill Companies, Inc., 2001; 1291–1327.
Shen JJ, Kurotaki N, Patel A, Lupski JR, Brown CW . Low factor XII level in an individual with Sotos syndrome. Pediatr Blood Cancer 2005; 44: 187–189.
Tans G, Rosing J . Structural and functional characterization of factor XII. Semin Thromb Hemost 1987; 13: 1–14.
Haanen C, Hommes F, Benraad H, Morselt G . A case of Hageman-factor deficiency and a method to purify the factor. Thromb Diath Haemorrh 1960; 5: 201–217.
Didisheim P . Hageman factor deficiency (Hageman trait). Case report and review of the literature. Arch Intern Med 1962; 110: 170–177.
Ikkala E, Myllylä G, Nevanlinna HR . Rare congenital coagulation factor defects in Finland. Scand J Haematol 1971; 8: 210–215.
Souto JC, Almasy L, Borrell M, Blanco-Vaca F, Mateo J, Soria JM et al. Genetic susceptibility to thrombosis and its relationship to physiological risk factors: The GAIT study. Am J Hum Genet 2000; 67: 1452–1459.
Soria JM, Almasy L, Souto JC, Bacq D, Buil A, Faure A et al. A quantitative-trait locus in the human factor XII gene influences both plasma factor XII levels and susceptibility to thrombotic disease. Am J Hum Genet 2002; 70: 567–574.
Tirado I, Soria JM, Mateo J, Oliver A, Souto JC, Santamaria A et al. Association after linkage analysis indicates that homozygosity for the 46C→T polymorphism in the F12 gene is a genetic risk factor for venous thrombosis. Thromb Haemost 2004; 91: 899–904.
Girolami A, Randi ML, Gavasso S, Lombardi AM, Spiezia F . The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors: A study of prevalence in 21 patients and review of the literature. J Thromb Thrombolysis 2004; 17: 139–143.
Endler G, Mannhalter C, Sunder-Plassmann H, Lalouschek W, Kapiotis S, Exner M et al. Homozygosity for the C→T polymorphism at nucleotide 46 in the 5′ untranslated region of the factor XII gene protects from development of acute coronary syndrome. Br J Haematol 2001; 115: 1007–1009.
Colhoun HM, Zito F, Chan NN, Rubens MB, Fuller JH, Humphries SE . Activated factor XII levels and factor XII 46C>T genotype in relation to coronary artery calcification in patients with type 1 diabetes and healthy subjects. Atherosclerosis 2002; 163: 363–369.
Zito F, Lowe GDO, Rumley A, McMahon AD, Humphries SE, on behalf of the WOSCOPS Study Group. Association of the factor XII 46C>T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study. Atherosclerosis 2002; 165: 153–158.
Miyata T, Kawabata S-I, Iwanaga S, Takahashi I, Alving B, Saito H . Coagulation factor XII (Hageman factor) Washington D.C.: Inactive factor XIIa results from Cys-571→Ser substitution. Proc Natl Acad Sci U S A 1989; 86: 8319–8322.
Hovinga JK, Schaller J, Stricker H, Wuillemin WA, Furlan M, Lämmle B . Coagulation factor XII Locarno: The functional defect is caused by the amino acid substitution Arg 353→Pro leading to loss of a kallikrein cleavage site. Blood 1994; 84: 1173–1181.
Schloesser M, Hofferbert S, Bartz U, Lutze G, Lämmle B, Engel W . The novel acceptor splice site mutation 11396(G→A) in the factor XII gene causes a truncated transcript in cross-reacting material negative patients. Hum Mol Genet 1995; 4: 1235–1237.
Schloesser M, Zeerleder S, Lutze G, Halbmayer W-M, Hofferbert S, Hinney B et al. Mutations in the human factor XII gene. Blood 1997; 90: 3967–3977.
Kondo S, Tokunaga F, Kawano S, Oono Y, Kumagai S, Koide T . Factor XII Tenri, a novel cross-reacting material negative factor XII deficiency, occurs through a proteasome-mediated degradation. Blood 1999; 93: 4300–4308.
Kanaji T, Kanaji S, Osaki K, Kuroiwa M, Sakaguchi M, Mihara K et al. Identification and characterization of two novel mutations (Q421K and R123P) in congenital factor XII deficiency. Thromb Haemost 2001; 86: 1409–1415.
Wada H, Nishioka J, Kasai Y, Kato-Nakazawa K, Abe Y, Morishita Y . Molecular characterization of coagulation factor XII deficiency in a Japanese family. Thromb Haemost 2003; 90: 59–63.
Ishii K, Oguchi S, Moriki T, Yatabe Y, Takeshita E, Murata M et al. Genetic analyses and expression studies identified a novel mutation (W486C) as a molecular basis of congenital coagulation factor XII deficiency. Blood Coagul Fibrinolysis 2004; 15: 367–373.
Kanaji T, Okamura T, Osaki K, Kuroiwa M, Shimoda K, Hamasaki N et al. A common genetic polymorphism (46 C to T substitution) in the 5′-untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level. Blood 1998; 91: 2010–2014.
Ishii K, Oguchi S, Murata M, Mitsuyoshi Y, Takeshita E, Ito D et al. Activated factor XII levels are dependent on factor XII 46 C/T genotypes and factor XII zymogen levels, and are associated with vascular risk factors in patients and healthy subjects. Blood Coagul Fibrinolysis 2000; 11: 277–284.
Höglund P, Kurotaki N, Kytölä S, Miyake N, Somer M, Matsumoto N . Familial Sotos syndrome is caused by a novel 1 bp deletion of the NSD1 gene. J Med Genet 2003; 40: 51–54.
Souto JC, Almasy L, Borrell M, Garí M, Martínez E, Mateo J et al. Genetic determinants of hemostasis phenotypes in Spanish families. Circulation 2000; 101: 1546–51.
Kitchens CS, Alexander JA . Partial deficiency of coagulation factor XI as a newly recognized feature of Noonan syndrome. J Pediatr 1983; 102: 224–227.
Sharland M, Patton MA, Talbot S, Chitolie A, Bevan DH . Coagulation-factor deficiencies and abnormal bleeding in Noonan's syndrome. Lancet 1992; 339: 19–21.
Bertola DR, Carneiro JDA, D'Amico EA, Kim CA, Albano LMJ, Sugayama SMM et al. Hematological findings in Noonan syndrome. Rev Hosp Clin Fac Med Sao Paulo 2003; 58: 5–8.
Pauer H-U, Renné T, Hemmerlein B, Legler T, Fritzlar S, Adham I et al. Targeted deletion of murine coagulation factor XII gene-a model for contact phase activation in vivo.. Thromb Haemost 2004; 92: 503–508.
Nagai T, Matsumoto N, Kurotaki N, Harada N, Niikawa N, Ogata T et al. Sotos syndrome and haploinsufficiency of NSD1: clinical features of intragenic mutations and submicroscopic deletions. J Med Genet 2003; 40: 285–289.
Lee ST, Nicholls RD, Bundey S, Laxova R, Musarella M, Spritz RA . Mutations of the P gene in oculocutaneous albinism, ocular albinism, and Prader-Willi syndrome plus albinism. N Engl J Med 1994; 330: 529–534.
Spritz RA, Bailin T, Nicholls RD, Lee S-T, Park S-K, Mascari MJ . Hypopigmentation in the Prader-Willi syndrome correlates with P gene deletion but not with haplotype of the hemizygous P allele. Am J Med Genet 1997; 71: 57–62.
Liburd N, Ghosh M, Riazuddin S, Naz S, Khan S, Ahmed Z et al. Novel mutations of MYO15A associated with profound deafness in consanguineous families and moderately severe hearing loss in a patient with Smith-Magenis syndrome. Hum Genet 2001; 109: 535–541.
Friedman TB, Hinnant JT, Ghosh M, Boger ET, Riazuddin S, Lupski JR et al. DFNB3, spectrum of MYO15A recessive mutant alleles and an emerging genotype-phenotype correlation. Adv Otorhinolaryngol 2002; 61: 124–130.
Walz K, Fonseca P, Lupski JR . Animal models for human contiguous gene syndromes and other genomic disorders. Genet Mol Biol 2004; 27: 305–320.
Comments
Post a Comment